Annual Reports in Medicinal Chemistry (eBook, ePUB)

• Format: ePub

Produktbeschreibung

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies. - Timely and critical reviews of important topics in medicinal chemistry

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 472
• Erscheinungstermin: 31. Dezember 2012
• Englisch
• ISBN-13: 9780123972149
• Artikelnr.: 43851222

Inhaltsangabe

Personal Essay

1. Reflections on Medicinal Chemistry at Merck, West Point


Paul S. Anderson




2. My Path in Seeking New Medicines


Peter R. Bernstein




3. Tales of Drug Discovery


M. Ross Johnson



I. Central Nervous System Diseases

Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts


4. Recent Developments in Targeting Neuroinflammation in Disease


Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal




5. Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease


Harrie J. M. Gijsen and François P. Bischoff




6. mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders


Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher




7. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments


Kamalesh B. Ruppa, Dalton King and Richard Olson




8. Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging


Lei Zhang and Anabella Villalobos



II. Cardiovascular and Metabolic Diseases

Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey


9. Case History: Eliquis^TM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases


Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler




10. AMPK Activation in Health and Disease


Iyassu K. Sebhat and Robert W. Myers




11. Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome


Juan C. Jaen, Jay P. Powers and Tim Sullivan




12. Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes


Philip A. Carpino and David Hepworth



III. Inflammatory Pulmonary and Gastrointestinal Diseases

Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey


13. Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists


Alaric J. Dyckman




14. Bifunctional Compounds for the Treatment of COPD


Gary Phillips and Michael Salmon




15. Inflammatory Targets for the Treatment of Atherosclerosis


Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi



IV. Oncology

Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia


16. Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook


Paul F. Richardson




17. Small-Molecule Antagonists of Bcl-2 Family Proteins


Sean P. Brown and Joshua P. Taygerly




18. Notch Pathway Modulators as Anti-Cancer Chemotherapeutics


Vibhavari Sail and M. Kyle Hadden




19. Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers


Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda



V. Infectious Diseases

Section Editor: John Primeau, Westford, Massachusetts


20. Recent Advances in the Discovery of Dengue Virus Inhibitors


Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand




21. Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB


Pravin S. Shirude and Shahul Hameed




22. HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replicati

Rezensionen

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --Enzymologia